Business UpdateJun 2, 2026, 07:31 AM
Optimi Health Completes GMP Psilocybin Production for Global Supply
AI Summary
Optimi Health Corp. announced the successful completion of a GMP production run for its 5mg psilocybin finished drug product. These capsules are already prescribed for treatment-resistant depression in Australia, and additional product from this run will support upcoming clinical trials in the United States and Europe. The company highlighted its vertically integrated manufacturing process, conducted entirely in-house under its Health Canada Drug Establishment Licence, positioning it as a key supplier for regulated psychedelic medicine.
Key Highlights
- Optimi Health completed a GMP production run of its 5mg psilocybin finished drug product.
- The 5mg psilocybin capsules are commercially prescribed for treatment-resistant depression in Australia.
- Additional product from this run is earmarked for planned clinical trials in the United States and Europe.
- All manufacturing stages were completed in-house under Optimi's Health Canada Drug Establishment Licence (DEL).
- The facility includes a Health Canada compliant Level 8 vault with capacity for up to C$100 million in controlled substances.
- Optimi is authorized to hold up to 20 kilograms of psilocybin and 2,000 kilograms of biomass on site.
Price Impact
More from OPTH